NCT05656040View on ClinicalTrials.gov

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

August 12, 2024

Study Completion Date

August 12, 2024

Conditions
End-Stage Renal DiseaseEnd-Stage Kidney DiseaseKidney Failure, Chronic
Interventions
BIOLOGICAL

MK-2060

MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously

DRUG

Placebo

Normal saline administered subcutaneously

Trial Locations (4)

32132

Velocity Clinical Research, New Smyrna Beach ( Site 0003), Edgewater

33147

Advanced Pharma CR, LLC ( Site 0006), Miami

33603

Genesis Clinical Research, LLC ( Site 0004), Tampa

37920

Alliance for Multispecialty Research, LLC ( Site 0002), Knoxville

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY